Antihypertensive Drugs Linked to Better Liver Outcomes in MASLD
In an international multicenter cohort of 4,302 individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and high blood pressure, renin–angiotensin system inhibitor (RASi) and calcium channel blocker (CCB) use was associated with more favorable liver outcomes and a lower risk of long-term liver-related events (LREs). Over a median follow-up of […]